CTLA4 and hepatocellular carcinoma: HepG2 cells treated with HCC-SDS mice serum had a stronger cell proliferation, and migration and invasion ability, while the CTLA-4 inhibitors could reverse these changes, indicating spleen deficiency may boost the occurrence and development of HCC via exosomal CTLA-4.